Swiss Rockets AG announces today the appointment of Albert Muntane Casanova as Chief Financial Officer of Swiss Rockets Group.  

Mr. Albert Muntane Casanova (47) started as the Chief Financial Officer for all the Swiss Rockets group companies. He is responsible for the finance, strategy, and investment functions.

He joined Swiss Rockets from Mitsubishi UFJ Financial Group (MUFG Bank), where he was Director Investment Banking in the global aviation finance office, formerly the Aviation Division of DVB Bank SE, based in London. During this five-year period his responsibilities included advising airlines and lessors on raising finance as well as on strategy. Prior to joining DVB Bank in 2016, he held management and strategy roles at Air Europa, Spanair, the Spanish Ministry of Foreign Affairs, Accenture, and SAP.

Throughout his career Mr. Muntane Casanova has lived in the UK, Germany, Bosnia & Herzegovina and Spain. Mr. Muntane Casanova holds a B.Sc. in Business Administration from the Universitat Autonoma de Barcelona and also holds a management degree from Instituto de Empresa Business School.

About Swiss Rockets AG

Founded in 2018, Swiss Rockets AG is implementing a paradigm shift in healthcare. Patients benefit from new treatments that are developed using innovative and forward-looking methods. The Swiss Rockets team combines the necessary expert knowledge and experience to create innovative medications, focusing mainly on cancer and viral diseases.

The founders of Swiss Rockets AG are Dr. Vladimir Cmiljanovic, Dr. Natasa Cmiljanovic, Manuel Ebner, Dr. Thomas Sander and Dr. Thomas Staehelin. Vladimir Cmiljanovic, the CEO, is a medicinal chemist, and entrepreneur with more than 15 years’ experience in developing cancer medications. He is the founder of the Swiss biotech companies PIQUR AG and TargImmune AG. Working with his sister Dr. Natasa Cmiljanovic, the Chief Scientific Officer of Swiss Rockets AG, he developed cancer medications at the University of Basel. Also, he has founded and managed several biotech firms. Manuel Ebner is the Managing Director of the Bank of America Merrill Lynch, Switzerland, and a strategic advisor to Swiss Rockets. Dr. Thomas Sander, one of the first employees of the biotech firm Actelion, is a scientific advisor to Swiss Rockets. Dr. Thomas Staehelin, co-founder of Swiss Rockets AG, is Executive Board Member and President of several shareholder companies and trusts.

Members of the Board of Directors of Swiss Rockets AG are Dr. Vladimir Cmiljanovic (Chair), Prof. Dr. Michael N. Hall, a renowned researcher and professor of the Centre for Molecular Life Sciences of the University of Basel, Dr. Natasa Cmiljanovic, a medicinal chemist and clinical scientist with experience in developing cancer medications, Dr. Thomas Ladner, a corporate lawyer, founder and co-founder of several successful start-ups and the World. Minds foundation, and André Debrunner, financial expert, and fund manager with Northern Trust Switzerland AG.